Higher levels of sEVs‐PD‐L1+ have been associated with a poor prognosis in a variety of tumor types [17] suggesting that sEVs‐PD‐L1+ are a promising biomarker for diagnosing and prognosing cancer, as well as for predicting responses to immune therapies. The gene discussed is CD274; the disease is cancer.